Table 3.

Icotinib in first-line therapy

Study	Number of Cases	Proportion of adenocarcinoma	OR	DCR	PFS, months	OS, months	Rash	Diarrhea	Dysfunction of liver
Yang et al37	56	100%	46.4%	78.6%	–	–	28.5%	10.7%	10.7%
He et al38	21	76.2%	42.9%	85.7%	7.2	–	33.3%	33.3%	9.5%
Quan et al39	34	58.8%	–	68.75%*	–	–	23.5%	20.6%	2.9%

Notes: *RR of pleural effusion was 71.88%; “–”, not available.

Abbreviations: DCR, disease control rate; OS, overall survival; PFS, progression-free survival.